/stocks — the workspaceLOADING
All UPBSEC filings, by type → · Earnings date & implied move · Search inside filings
Upstream Bio, Inc. (UPB) is a pharmaceutical preparations company. Piotroski F-Score 3/7. 11 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-11-04 from UPB's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind UPB’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from UPB’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on UPB plus an auto-SWOT — built from UPB's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate UPB using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has UPB been issuing shares? Offering history →
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
No tracked institution reported a position in UPB in the latest 13F round.
No lawmaker has disclosed a trade in UPB under the STOCK Act.
| Ambrose AllisonGeneral Counsel | SELL | $3K | view → |
| Deykin AaronChief Medical Officer | SELL | $5K | view → |
| Houghton AdamChief Business Officer | SELL | $4K | view → |
| Sutherland Everett RandChief Executive Officer | SELL | $13K | view → |
| GRAY MICHAELCFO and COO | SELL | $5K | view → |
| Houghton AdamChief Business Officer | SELL | $6K | view → |
| Ambrose AllisonGeneral Counsel | SELL | $4K | view → |
| Sutherland Everett RandChief Executive Officer | SELL | $19K | view → |
Projected from UPB's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentUPB files or announces.
UPB has sold off after 6 of its last 8 earnings reports.
Each figure is one earnings reaction — how much UPB moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Large earnings reactions have been common.
UPB has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+5.8% and -54.0%).
A more typical earnings reaction has been approximately ±5.7%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-11 | -7.1% |
| 2026-05-13 | -1.8% |
| 2026-03-26 | -8.4% |
| 2026-02-11 | -54.0% |
| 2025-11-05 | -5.5% |
| 2025-08-06 | +2.2% |
| 2025-05-06 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -1.2% |
| 2025-03-12 | +5.8% |
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.